791 related articles for article (PubMed ID: 26856534)
1. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?
Mueller TC; Bachmann J; Prokopchuk O; Friess H; Martignoni ME
BMC Cancer; 2016 Feb; 16():75. PubMed ID: 26856534
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms to explain wasting of muscle and fat in cancer cachexia.
Argilés JM; López-Soriano FJ; Busquets S
Curr Opin Support Palliat Care; 2007 Dec; 1(4):293-8. PubMed ID: 18685378
[TBL] [Abstract][Full Text] [Related]
3. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.
Martin A; Freyssenet D
J Cachexia Sarcopenia Muscle; 2021 Apr; 12(2):252-273. PubMed ID: 33783983
[TBL] [Abstract][Full Text] [Related]
5. Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.
Talbert EE; Guttridge DC
Semin Cell Dev Biol; 2016 Jun; 54():82-91. PubMed ID: 26385617
[TBL] [Abstract][Full Text] [Related]
6. Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.
Siddiqui JA; Pothuraju R; Jain M; Batra SK; Nasser MW
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188359. PubMed ID: 32222610
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
8. Skeletal muscle regeneration in cancer cachexia.
Bossola M; Marzetti E; Rosa F; Pacelli F
Clin Exp Pharmacol Physiol; 2016 May; 43(5):522-7. PubMed ID: 26857538
[TBL] [Abstract][Full Text] [Related]
9. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
Fukawa T; Yan-Jiang BC; Min-Wen JC; Jun-Hao ET; Huang D; Qian CN; Ong P; Li Z; Chen S; Mak SY; Lim WJ; Kanayama HO; Mohan RE; Wang RR; Lai JH; Chua C; Ong HS; Tan KK; Ho YS; Tan IB; Teh BT; Shyh-Chang N
Nat Med; 2016 Jun; 22(6):666-71. PubMed ID: 27135739
[TBL] [Abstract][Full Text] [Related]
10. Metabolic derangements of skeletal muscle from a murine model of glioma cachexia.
Cui P; Shao W; Huang C; Wu CJ; Jiang B; Lin D
Skelet Muscle; 2019 Jan; 9(1):3. PubMed ID: 30635036
[TBL] [Abstract][Full Text] [Related]
11. Signaling pathways controlling skeletal muscle mass.
Egerman MA; Glass DJ
Crit Rev Biochem Mol Biol; 2014; 49(1):59-68. PubMed ID: 24237131
[TBL] [Abstract][Full Text] [Related]
12. The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia.
Lan XQ; Deng CJ; Wang QQ; Zhao LM; Jiao BW; Xiang Y
Gen Comp Endocrinol; 2024 Jul; 353():114513. PubMed ID: 38604437
[TBL] [Abstract][Full Text] [Related]
13. Muscle wasting: an overview of recent developments in basic research.
Palus S; von Haehling S; Springer J
Int J Cardiol; 2014 Oct; 176(3):640-4. PubMed ID: 25205489
[TBL] [Abstract][Full Text] [Related]
14. Muscle wasting in cancer.
Johns N; Stephens NA; Fearon KC
Int J Biochem Cell Biol; 2013 Oct; 45(10):2215-29. PubMed ID: 23770121
[TBL] [Abstract][Full Text] [Related]
15. SIRT1-NOX4 signaling axis regulates cancer cachexia.
Dasgupta A; Shukla SK; Vernucci E; King RJ; Abrego J; Mulder SE; Mullen NJ; Graves G; Buettner K; Thakur R; Murthy D; Attri KS; Wang D; Chaika NV; Pacheco CG; Rai I; Engle DD; Grandgenett PM; Punsoni M; Reames BN; Teoh-Fitzgerald M; Oberley-Deegan R; Yu F; Klute KA; Hollingsworth MA; Zimmerman MC; Mehla K; Sadoshima J; Tuveson DA; Singh PK
J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32441762
[TBL] [Abstract][Full Text] [Related]
16. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia.
Acharyya S; Butchbach ME; Sahenk Z; Wang H; Saji M; Carathers M; Ringel MD; Skipworth RJ; Fearon KC; Hollingsworth MA; Muscarella P; Burghes AH; Rafael-Fortney JA; Guttridge DC
Cancer Cell; 2005 Nov; 8(5):421-32. PubMed ID: 16286249
[TBL] [Abstract][Full Text] [Related]
17. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
[TBL] [Abstract][Full Text] [Related]
18. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?
Dolly A; Dumas JF; Servais S
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1413-1428. PubMed ID: 33053604
[TBL] [Abstract][Full Text] [Related]
19. Cancer cachexia: molecular mechanism and pharmacological management.
Li Y; Jin H; Chen Y; Huang T; Mi Y; Zou Z
Biochem J; 2021 May; 478(9):1663-1688. PubMed ID: 33970218
[TBL] [Abstract][Full Text] [Related]
20. Impaired Muscle Regeneration in Cancer-Associated Cachexia.
Arneson PC; Doles JD
Trends Cancer; 2019 Oct; 5(10):579-582. PubMed ID: 31706505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
